Myriad Genetics (MYGN) News Today $7.70 +0.14 (+1.85%) Closing price 04:00 PM EasternExtended Trading$7.70 0.00 (-0.06%) As of 05:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period What To Expect From Myriad Genetics’s (MYGN) Q1 EarningsMay 5 at 10:17 AM | msn.comMyriad Genetics: Significantly Undervalued With Profitability In SightMay 2 at 1:27 AM | seekingalpha.com1 Unprofitable Stock to Target This Week and 2 to Be Wary OfMay 1, 2025 | finance.yahoo.comMyriad Genetics (MYGN) Projected to Post Earnings on TuesdayMyriad Genetics (NASDAQ:MYGN) will be releasing its Q1 2025 earnings before the market opens on Tuesday, May 6. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-6-myriad-genetics-inc-stock/)May 1, 2025 | marketbeat.comMyriad Genetics to Release First Quarter 2025 Financial Results on May 6, 2025May 1, 2025 | seekingalpha.comMyriad Genetics (NASDAQ:MYGN) Reaches New 1-Year Low - What's Next?Myriad Genetics (NASDAQ:MYGN) Hits New 1-Year Low - What's Next?April 30, 2025 | marketbeat.comMyriad Genetics (MYGN) Survey Highlights Views on Mental Health Medication | MYGN Stock NewsApril 30, 2025 | gurufocus.comConcerns about Mental Health Medication Side Effects Remain a Barrier to Getting Help for Those Diagnosed with Depression and Anxiety, According to the GeneSight Mental Health MonitorApril 30, 2025 | globenewswire.comMyriad Genetics, Inc. (NASDAQ:MYGN) Given Average Rating of "Hold" by AnalystsMyriad Genetics, Inc. (NASDAQ:MYGN - Get Free Report) has been given an average recommendation of "Hold" by the sixteen brokerages that are covering the stock, MarketBeat reports. Three research analysts have rated the stock with a sell recommendation, seven have assigned a hold recommendation andApril 28, 2025 | marketbeat.comWells Fargo & Company MN Purchases 87,659 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN)Wells Fargo & Company MN raised its position in shares of Myriad Genetics, Inc. (NASDAQ:MYGN - Free Report) by 69.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 214,127 shares of the company's stockApril 26, 2025 | marketbeat.comMyriad Genetics Highlights MRD Clinical Validity Data at American Association for Cancer ...April 25, 2025 | gurufocus.comMyriad Genetics Highlights MRD Clinical Validity Data at American Association for Cancer ...April 25, 2025 | gurufocus.comMyriad Genetics Unveils Promising Clinical Data on Precise MRD Test for Oligometastatic Clear-Cell Renal Cell Carcinoma at AACR Annual MeetingApril 25, 2025 | quiverquant.comMyriad Genetics Highlights MRD Clinical Validity Data at American Association for Cancer Research Annual MeetingApril 25, 2025 | globenewswire.comMyriad Genetics Q3 EPS Forecast Increased by Leerink PartnrsMyriad Genetics, Inc. (NASDAQ:MYGN - Free Report) - Research analysts at Leerink Partnrs increased their Q3 2025 earnings per share estimates for shares of Myriad Genetics in a report issued on Monday, April 21st. Leerink Partnrs analyst P. Souda now forecasts that the company will earn ($0.05) pApril 25, 2025 | marketbeat.comInvesco Ltd. Has $10.55 Million Position in Myriad Genetics, Inc. (NASDAQ:MYGN)Invesco Ltd. increased its holdings in shares of Myriad Genetics, Inc. (NASDAQ:MYGN - Free Report) by 37.9% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 769,284 shares of the company's stock after buyingApril 25, 2025 | marketbeat.comLeerink Partners Sticks to Its Hold Rating for Myriad Genetics (MYGN)April 23, 2025 | markets.businessinsider.comMyriad Genetics (NASDAQ:MYGN) Hits New 52-Week Low - Here's WhyMyriad Genetics (NASDAQ:MYGN) Reaches New 12-Month Low - Time to Sell?April 23, 2025 | marketbeat.comMyriad says GeneSight Psychotropic Test led to fewer hospitalizations in studyApril 21, 2025 | msn.comMyriad Genetics Announces Study Results Show Patients with Depression had Fewer Psychiatric Hospitalizations after GeneSight TestingApril 21, 2025 | globenewswire.comFederated Hermes Inc. Sells 47,999 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN)Federated Hermes Inc. lowered its position in shares of Myriad Genetics, Inc. (NASDAQ:MYGN - Free Report) by 84.8% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 8,600 shares of the company's stock after selling 47,999 shApril 21, 2025 | marketbeat.comRenaissance Technologies LLC Grows Stock Holdings in Myriad Genetics, Inc. (NASDAQ:MYGN)Renaissance Technologies LLC raised its stake in shares of Myriad Genetics, Inc. (NASDAQ:MYGN - Free Report) by 87.4% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 684,874 shares of the company's stock after acquApril 20, 2025 | marketbeat.comJPMorgan Chase & Co. Has $5.83 Million Position in Myriad Genetics, Inc. (NASDAQ:MYGN)JPMorgan Chase & Co. cut its stake in Myriad Genetics, Inc. (NASDAQ:MYGN - Free Report) by 24.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 425,244 shares of the company's stock after selling 140,886 shares during tApril 20, 2025 | marketbeat.comMyriad Genetics, Inc. (NASDAQ:MYGN) Shares Bought by XTX Topco LtdXTX Topco Ltd raised its stake in shares of Myriad Genetics, Inc. (NASDAQ:MYGN - Free Report) by 474.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 64,080 shares of the company's stock after purchaApril 19, 2025 | marketbeat.comCapital Fund Management S.A. Invests $1.20 Million in Myriad Genetics, Inc. (NASDAQ:MYGN)Capital Fund Management S.A. purchased a new stake in shares of Myriad Genetics, Inc. (NASDAQ:MYGN - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 87,555 shares of the company's stock, valued at approximately $1,200,000. CapApril 18, 2025 | marketbeat.comDemystifying Myriad Genetics: Insights From 10 Analyst ReviewsApril 17, 2025 | benzinga.comMyriad Genetics price target lowered to $9 from $11 at BofAApril 15, 2025 | finance.yahoo.comMyriad Genetics price target lowered to $9 from $11 at BofAApril 15, 2025 | markets.businessinsider.comMyriad Genetics (MYGN) Sees Price Target Lowered by BofA Amid Policy Concerns | MYGN Stock NewsApril 14, 2025 | gurufocus.comTrexquant Investment LP Decreases Position in Myriad Genetics, Inc. (NASDAQ:MYGN)Trexquant Investment LP lowered its position in shares of Myriad Genetics, Inc. (NASDAQ:MYGN - Free Report) by 31.5% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 92,376 shares of the company's stock after selling 42,569April 12, 2025 | marketbeat.comMyriad Genetics (NASDAQ:MYGN) Upgraded by StockNews.com to Buy RatingStockNews.com upgraded shares of Myriad Genetics from a "hold" rating to a "buy" rating in a research report on Thursday.April 12, 2025 | marketbeat.comMyriad Genetics (NASDAQ:MYGN) Shares Gap Down - Should You Sell?Myriad Genetics (NASDAQ:MYGN) Shares Gap Down - Time to Sell?April 11, 2025 | marketbeat.comMyriad Genetics (NASDAQ:MYGN) Stock Rating Lowered by GuggenheimGuggenheim cut shares of Myriad Genetics from a "buy" rating to a "neutral" rating in a research report on Wednesday.April 11, 2025 | marketbeat.comGuggenheim Downgrades Myriad Genetics (MYGN)April 10, 2025 | msn.comMyriad Genetics downgraded to Neutral from Buy at GuggenheimApril 9, 2025 | markets.businessinsider.comMyriad Genetics (NASDAQ:MYGN) Hits New 52-Week Low - Time to Sell?Myriad Genetics (NASDAQ:MYGN) Hits New 12-Month Low - Time to Sell?April 9, 2025 | marketbeat.comVanguard Group Inc. Boosts Stock Position in Myriad Genetics, Inc. (NASDAQ:MYGN)Vanguard Group Inc. boosted its holdings in shares of Myriad Genetics, Inc. (NASDAQ:MYGN - Free Report) by 2.7% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 10,591,043 shares of the company's stock afApril 9, 2025 | marketbeat.comMyriad Genetics, Inc.: Myriad Genetics Names Brian Donnelly as New Chief Commercial OfficerApril 8, 2025 | finanznachrichten.deMyriad Genetics Announces Inducement AwardsApril 8, 2025 | globenewswire.comMyriad Genetics appoints Brian Donnelly as CCOApril 8, 2025 | markets.businessinsider.comMyriad Genetics Names Brian Donnelly as New Chief Commercial OfficerApril 7, 2025 | gurufocus.comMyriad Genetics Names Brian Donnelly as New Chief Commercial OfficerApril 7, 2025 | globenewswire.comWellington Management Group LLP Sells 711,985 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN)Wellington Management Group LLP lowered its position in Myriad Genetics, Inc. (NASDAQ:MYGN - Free Report) by 10.6% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 6,004,598 shares of the company's stock after selling 711,985April 7, 2025 | marketbeat.comPictet Asset Management Holding SA Cuts Stake in Myriad Genetics, Inc. (NASDAQ:MYGN)Pictet Asset Management Holding SA lessened its stake in shares of Myriad Genetics, Inc. (NASDAQ:MYGN - Free Report) by 7.0% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 479,808 shares of the company's stock after selling 36,262 shares during theApril 5, 2025 | marketbeat.comPrudential Financial Inc. Sells 126,550 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN)Prudential Financial Inc. lessened its stake in shares of Myriad Genetics, Inc. (NASDAQ:MYGN - Free Report) by 37.7% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 209,131 shares of the company's stockApril 4, 2025 | marketbeat.com10 Analysts Assess Myriad Genetics: What You Need To KnowApril 3, 2025 | nasdaq.comMyriad Genetics (NASDAQ:MYGN) Cut to Hold at StockNews.comStockNews.com downgraded Myriad Genetics from a "buy" rating to a "hold" rating in a report on Wednesday.April 3, 2025 | marketbeat.comScotiabank Lowers Myriad Genetics (NASDAQ:MYGN) Price Target to $20.00Scotiabank decreased their target price on shares of Myriad Genetics from $24.00 to $20.00 and set a "sector outperform" rating for the company in a research note on Tuesday.April 2, 2025 | marketbeat.comMyriad Genetics (NASDAQ:MYGN) Sets New 12-Month Low - What's Next?Myriad Genetics (NASDAQ:MYGN) Hits New 52-Week Low - What's Next?April 2, 2025 | marketbeat.comMyriad Genetics, Inc. (NASDAQ:MYGN) Receives Consensus Rating of "Hold" from AnalystsShares of Myriad Genetics, Inc. (NASDAQ:MYGN - Get Free Report) have earned a consensus rating of "Hold" from the fifteen analysts that are presently covering the firm, MarketBeat reports. Three investment analysts have rated the stock with a sell rating, six have given a hold rating and six have gApril 2, 2025 | marketbeat.com Get Myriad Genetics News Delivered to You Automatically Sign up to receive the latest news and ratings for MYGN and its competitors with MarketBeat's FREE daily newsletter. Email Address MYGN Media Mentions By Week MYGN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MYGN News Sentiment▼0.050.72▲Average Medical News Sentiment MYGN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MYGN Articles This Week▼88▲MYGN Articles Average Week Get Myriad Genetics News Delivered to You Automatically Sign up to receive the latest news and ratings for MYGN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies FOLD News LGND News BCRX News MNKD News CLDX News DVAX News INVA News NVAX News OPK News GERN News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MYGN) was last updated on 5/5/2025 by MarketBeat.com Staff From Our PartnersWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTrump to solve American wealth loss?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredU.S. Stock Market Now on Verge of CollapseThe last time the U.S. economy looked like this, stocks didn't move for 16 years... And many investors lost...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Myriad Genetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Myriad Genetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MYGN Stock Free MYGN Stock Alerts